作者：
Darpo,B. [1]
;
Garnett,C. [2]
;
Benson,C.T. [3]
;
Keirns,J. [4]
;
Leishman,D. [5]
;
Malik,M. [6]
;
Mehrotra,N. [7]
;
Prasad,K. [8]
;
Riley,S. [9]
;
Rodriguez,I. [10]
;
Sager,P. [11]
;
Sarapa,N. [12]
;
Wallis,R. [13]
作者单位：
St Paul's Cardiac Electrophysiology, University of London, Imperial College, London, United Kingdom
[1]
Lilly Corporate Center, Eli Lilly and Co, Indianapolis, IN, United States
[2]
Karolinska Institutet, Department of Clinical Sciences, Danderyd's Hospital, Stockholm, Sweden
[3]
Global PK/PD and Pharmacometrics, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN
[4]
Medicines and Healthcare Products Regulatory Agency, DoH, London, United Kingdom
[5]
Division of Pharmacometrics, Center for Drug Evaluation and Research, United States Food and Drug
[6]
Safety Pharmacology Consultant, Sandwich, United Kingdom
[7]
Certara, St Louis, MO, United States
[8]
Clinical Pharmacology, Global Innovative Pharma Business, Pfizer Inc., Groton, CT, United States
[9]
Pharma Development Safety Risk Management, Roche TCRC, Inc., New York, NY, United States
[10]
Global Clinical Pharmacology and Exploratory Development, Astellas Pharma Global, Development, Inc
[11]
Stanford School of Medicine, Palo Alto, CA, United States
[12]
Clinical Sciences, Bayer Healthcare, Inc., Whippany, NJ, United States
[13]
发布时间
2018-07-27
换一批
